HomeCompareRYPNX vs MRK

RYPNX vs MRK: Dividend Comparison 2026

RYPNX yields 9.05% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $20.4K in total portfolio value· pulled ahead in Year 6
10 years
RYPNX
RYPNX
● Live price
9.05%
Share price
$16.87
Annual div
$1.53
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$36.4K
Annual income
$1,602.33
Full RYPNX calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — RYPNX vs MRK

📍 MRK pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRYPNXMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RYPNX + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RYPNX pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RYPNX
Annual income on $10K today (after 15% tax)
$769.59/yr
After 10yr DRIP, annual income (after tax)
$1,361.98/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $6,966.43/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RYPNX + MRK for your $10,000?

RYPNX: 50%MRK: 50%
100% MRK50/50100% RYPNX
Portfolio after 10yr
$46.6K
Annual income
$5,700.24/yr
Blended yield
12.23%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

RYPNX
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RYPNX buys
0
MRK buys
0
No recent congressional trades found for RYPNX or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRYPNXMRK
Forward yield9.05%2.76%
Annual dividend / share$1.53$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$36.4K$56.8K
Annual income after 10y$1,602.33$9,798.13
Total dividends collected$12.6K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RYPNX vs MRK ($10,000, DRIP)

YearRYPNX PortfolioRYPNX Income/yrMRK PortfolioMRK Income/yrGap
1$11,605$905.39$11,206$366.19+$399.00RYPNX
2$13,400$982.01$12,650$502.35+$750.00RYPNX
3$15,397$1,059.66$14,407$694.19+$990.00RYPNX
4$17,613$1,137.98$16,585$967.82+$1.0KRYPNX
5$20,063$1,216.58$19,342$1,363.89+$721.00RYPNX
6← crossover$22,762$1,295.12$22,913$1,947.19$151.00MRK
7$25,729$1,373.25$27,662$2,823.89$1.9KMRK
8$28,981$1,450.68$34,159$4,173.35$5.2KMRK
9$32,536$1,527.12$43,337$6,308.80$10.8KMRK
10$36,416$1,602.33$56,776$9,798.13$20.4KMRK

RYPNX vs MRK: Complete Analysis 2026

RYPNXStock

The fund’s investment adviser invests the fund’s assets primarily in equity securities of small-cap companies in an attempt to take advantage of what the adviser believes are opportunistic situations for undervalued securities. It invests at least 80% of its net assets in securities of small-cap companies, under normal circumstances. It may invest in other investment companies that invest in equity securities.

Full RYPNX Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this RYPNX vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RYPNX vs SCHDRYPNX vs JEPIRYPNX vs ORYPNX vs KORYPNX vs MAINRYPNX vs JNJRYPNX vs ABBVRYPNX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.